News &

Media Contact

Amy Merves
Manager of
Media Relations



Fox Chase Cancer Center's Gerald Hanks Named to First Class of ASTRO Fellows

PHILADELPHIA (Nov. 5, 2006) The American Society for Therapeutic Radiology and Oncology has named Gerald Hanks, MD, retired chairman of radiation oncology at Fox Chase Cancer Center, to its first class of fellows.

Hanks received his FASTRO designation today at a special ceremony during the Society's 48th Annual Meeting in Philadelphia.

"We created the ASTRO Fellows program to honor and recognize those who have given so much to the specialty of radiation oncology, the Society and the patients we all work together to cure," said Prabhakar Tripuraneni, M.D., chairman of the ASTRO Board of Directors. "ASTRO has many members who are worthy of this great distinction and we are pleased to bestow on them this honor."

Members of ASTRO are eligible to become a Fellow if they have been part of the Society for at least 20 years, served in a leadership role for the organization and have made a significant contribution to the field of radiation oncology. The primary pathways to becoming a Fellow are research, patient care, education and leadership/service. The Society values contributions to all four areas, however, each nominee needed to have a truly outstanding contribution to at least one of the pathways to be named a Fellow.

Hanks is a past-president of ASTRO. In 1994, ASTRO awarded him Gold Medal for his outstanding contributions to the development of therapeutic radiology and oncology.

Hanks pioneered the use of three-dimensional, conformal radiation therapy to eradicate prostate cancer while sparing normal cells and reducing side effects of treatment. For men at high risk of prostate cancer, he created the Prostate Cancer Risk Assessment Program at Fox Chase. Hanks retired in 2001 and now resides in Healdsburg, Calif. Fox Chase named an endowed chair in his honor. Alan Pollack, M.D., Ph.D., current holds The Gerald E. Hanks Endowed Chair in Radiation Oncology.

ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 2006 News Releases »